Array BioPharma, Inc.

Biopharmaceutical firm exercises over-allotment option, completes offering

Published in Lab Business Week, January 23rd, 2005

Array BioPharma, Inc., (ARRY) announced the completion of its offering of 8,000,000 shares of common stock and of 1,200,000 additional shares pursuant to the exercise of an over-allotment option granted to UBS Investment Bank.

Including the sale of these additional shares, Array completed the offering for 9,200,000 shares of common stock at $7.75 per share, resulting in net proceeds of approximately $67 million.

Array anticipates using the net proceeds from this offering to fund research and development efforts, including clinical trials for its proprietary candidates; and for general corporate purposes, including working capital.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry